7,152 Shares in DaVita Inc. $DVA Acquired by Westwind Capital

Westwind Capital purchased a new position in shares of DaVita Inc. (NYSE:DVA) during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 7,152 shares of the company’s stock, valued at approximately $1,251,000.

Several other hedge funds have also made changes to their positions in the stock. CoreCap Advisors LLC grew its stake in DaVita by 161.7% during the 3rd quarter. CoreCap Advisors LLC now owns 157 shares of the company’s stock worth $27,000 after buying an additional 97 shares during the last quarter. Root Financial Partners LLC increased its holdings in shares of DaVita by 128.0% in the 1st quarter. Root Financial Partners LLC now owns 187 shares of the company’s stock worth $29,000 after acquiring an additional 105 shares during the period. Compass Financial Management LLC bought a new stake in DaVita in the 2nd quarter valued at about $72,000. Sankala Group LLC acquired a new position in DaVita during the 4th quarter valued at about $39,000. Finally, NewEdge Advisors LLC grew its position in DaVita by 66.4% in the 2nd quarter. NewEdge Advisors LLC now owns 361 shares of the company’s stock worth $80,000 after purchasing an additional 144 shares during the last quarter. Institutional investors own 90.12% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. Wall Street Zen downgraded DaVita from a “buy” rating to a “hold” rating in a research report on Saturday, September 26th. Raymond James Financial set a $220.00 target price on DaVita in a research note on Friday, August 7th. UBS Group boosted their price target on DaVita from $235.00 to $270.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Oppenheimer set a $220.00 price target on DaVita in a research note on Friday, August 7th. Finally, Barclays lifted their price objective on shares of DaVita from $218.00 to $224.00 and gave the company an “equal weight” rating in a research note on Wednesday, August 5th. Three analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, DaVita currently has a consensus rating of “Hold” and an average target price of $233.43.

DaVita Price Performance

Shares of DaVita stock traded down $0.34 during trading on Thursday, hitting $176.44. The stock had a trading volume of 582,204 shares, compared to its average volume of 901,968. The business has a fifty day moving average of $184.82 and a two-hundred day moving average of $189.41. DaVita Inc. has a fifty-two week low of $101.00 and a fifty-two week high of $247.49. The firm has a market cap of $11.26 billion, a P/E ratio of 14.44, a PEG ratio of 0.47 and a beta of 0.80.

DaVita (NYSE:DVA) last released its earnings results on Tuesday, August 4th. The company reported $4.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.88 by $0.14. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%.The firm had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.50 billion. During the same period in the previous year, the company earned $2.95 earnings per share. DaVita’s revenue was up 5.2% compared to the same quarter last year. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, research analysts forecast that DaVita Inc. will post 14.57 earnings per share for the current year.

DaVita Profile

DaVita Inc is a healthcare company focused on kidney care and renal disease management. Through its DaVita Kidney Care business, the company provides outpatient dialysis treatments for people with end-stage kidney disease, including hemodialysis and peritoneal dialysis, as well as home dialysis support.

The company also operates hospital-based dialysis programs and offers clinical, administrative and care-coordination services intended to support patients across the kidney-care journey.